SF
AIMT

Synovus Financial’s Aimmune Therapeutics AIMT Stock Holding History

Synovus Financial’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-136
Closed -$2K – 1604
2020
Q2 		$2K Sell
136
-800
-85% -$13.6K ﹤0.01% 1456
2020
Q1 		$14K Buy
936
+800
+588% +$20.4K ﹤0.01% 1489
2019
Q4 		$5K Hold
136
– – ﹤0.01% 1327
2019
Q3 		$3K Hold
136
– – ﹤0.01% 1371
2019
Q2 		$3K Hold
136
– – ﹤0.01% 1307
2019
Q1 		$3K Hold
136
– – ﹤0.01% 1326
2018
Q4 		$3K Hold
136
– – ﹤0.01% 1296
2018
Q3 		$4K Buy
+136
New +$3.85K ﹤0.01% 1282

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Synovus Financial's AIMT Position: Q3 2020 in Review

Synovus Financial sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 136 shares — an estimated $2K sold.

Synovus Financial first reported a position in AIMT in Q3 2018 and held it in 8 quarters. The position peaked at $14K in Q1 2020. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Synovus Financial reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Synovus Financial sold 136 Aimmune Therapeutics shares in Q3 2020, an estimated $2K.
  • Synovus Financial first reported a position in Aimmune Therapeutics in Q3 2018 and held it in 8 quarters.
  • Synovus Financial's Aimmune Therapeutics position peaked at $14K in Q1 2020.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Synovus Financial's 13F filing for Q3 2020, filed 9 Nov 2020.